This is a preview of subscription content, log in via an institution to check access.
References
Balboni B, El Hassouni B, Honeywell RJ, Sarkisjan D, Giovannetti E, Poore J, Heaton C, Peterson C, Benaim E, Lee YB, Kim DJ, Peters GJ (2019) RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. Expert Opin Investig Drugs 28(4):311–322. https://doi.org/10.1080/13543784.2019.1583742
Choy ATF, Carnevale I, Coppola S, Meijer LL, Kazemier G, Zaura E, Deng D, Giovannetti E (2018) The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine. Expert Rev Mol Diagn 18(12):1005–1009. https://doi.org/10.1080/14737159.2018.1544495
Dai Y, Zhong F, Liu W, Song Q, Hu W (2021) Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-021-03547-0
El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E (2019) Pharmacogenetics of treatments for pancreatic cancer. Expert Opin Drug Metab Toxicol 15(6):437–447. https://doi.org/10.1080/17425255.2019.1620731
Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R (2017) Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357(6356):1156–1160. https://doi.org/10.1126/science.aah5043
Halley A, Leonetti A, Gregori A, Tiseo M, Deng DM, Giovannetti E, Peters GJ (2020) The role of the microbiome in cancer and therapy efficacy: focus on lung cancer. Anticancer Res 40(9):4807–4818. https://doi.org/10.21873/anticanres.14484
Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M (2019) Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 121(9):725–737. https://doi.org/10.1038/s41416-019-0573-8
Marqueza VE, Schroeder GK, Ludek OR, Siddiqui MA, Ezzitouni A, Wolfenden R (2009) Contrasting behavior of conformationally locked carbocyclic nucleosides of adenosine and cytidine as substrates for deaminases. Nucleosides Nucleotides Nucleic Acids 28(5):614–632. https://doi.org/10.1080/15257770903091904
Vyse S, Huang PH (2019) Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther 4:5. https://doi.org/10.1038/s41392-019-0038-9
Zhang Y, Kang S, Fang W, Hong S, Liang W, Yan Y, Qin T, Tang Y, Sheng J, Zhang L (2015) Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis. Clin Lung Cancer 16(2):144-151.e1. https://doi.org/10.1016/j.cllc.2014.09.008
Funding
AL and MT are supported by the AIRC-IG grant# 20,074, AG and EG are supported by the KWF Grant#19,571, GJP and EG are supported by the Polish National Science Center Grant#2018/31/B/NZ7/02,909, DD and EG are supported by Cancer Center Amsterdam Grants 2016 and 2018, EG is supported by the AIRC-IG grant#24,444.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
MT has been on advisory boards and received speakers’ fees for Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre. MT has received research grants from Astra-Zeneca and Boehringer Ingelheim. AL received speakers’ fees for Astra-Zeneca.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Leonetti, A., Carbone, D., Gregori, A. et al. A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?. J Cancer Res Clin Oncol 147, 3135–3137 (2021). https://doi.org/10.1007/s00432-021-03647-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-021-03647-x